3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
PRETEXT I Hepatoblastoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Carcinoma, Transitional Cell
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
larotrectinib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
temsirolimus
×
30 days
×
Clear all
No trials found.